CSIMarket


Dynavax Technologies Corporation  (DVAX)
Other Ticker:  
 

Dynavax Technologies Corporation

DVAX's Fundamental analysis








Dynavax Technologies's sales fell by -59.15 % in III. Quarter 2023 from the same quarter a year ago. Ranking at No. 3785

Major Pharmaceutical Preparations industry recorded deterioration of revenues by -4.74 %

Dynavax Technologies's net profit deacreased by -77.6 % in III. Quarter 2023 year on year, to $14 millions.

More on DVAX's Growth


Dynavax Technologies
current PE on trailing twelve month basis is below Major Pharmaceutical Preparations industry average.

Dynavax Technologies realized cash outflow of $ -0.29per share in trailing twelve-month period.
Company
39.36
PE TTM   
Industry
351.15
PE TTM    
Company's Price to Sales ratio is at 5.07.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.43.


More on DVAX's Valuation
 
 Total Debt (Millions $) 222
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 1,532,681
 Net Income/Employee (TTM) $ 258,902
 Receivable Turnover (TTM) 4.28
 Tangible Book Value (Per Share $) 3.91

Dynavax Technologies
current PE on trailing twelve month basis is below Major Pharmaceutical Preparations industry average.

Dynavax Technologies realized cash outflow of $ -0.29per share in trailing twelve-month period.
Company
39.36
PE TTM   
Industry
351.15
PE TTM    
Company's Price to Sales ratio is at 5.07.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.43.

Dynavax Technologies Price to Book Ratio is at 3.02 lower than Indusry Avg. of 1542.66. and higher than S&P 500 Avg. of 0.01

More on DVAX's Valuation

  Market Capitalization (Millions $) 1,826
  Shares Outstanding (Millions) 154
  Employees 235
  Revenues (TTM) (Millions $) 360
  Net Income (TTM) (Millions $) 61
  Cash Flow (TTM) (Millions $) -44
  Capital Exp. (TTM) (Millions $) -4
  Total Debt (Millions $) 222
  Dividend TTM ($) 0 $
  Dividend Yield TTM (%) -
  Revenue/Employee (TTM) $ 1,532,681
  Net Income/Employee(TTM) $ 258,902
  Receivable Turnover Ratio (TTM) 4.28
  Tangible Book Value (Per Share $) 3.91

  Market Capitalization (Millions $) 1,826
  Shares Outstanding (Millions) 154
  Employees 235
  Revenues (TTM) (Millions $) 360
  Net Income (TTM) (Millions $) 61
  Cash Flow (TTM) (Millions $) -44
  Capital Exp. (TTM) (Millions $) -4


    DVAX's Profitability Comparisons
Dynavax Technologies achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in III. Quarter 2023 to 7.47 %.

Dynavax Technologies net profit margin of 20.86 % is currently ranking no. 34 in Major Pharmaceutical Preparations industry, ranking no. 61 in Healthcare sector and number 719 in S&P 500.





  Ratio
   Capital Ratio (MRQ) 15.4
  Total Debt to Equity (MRQ) 0.37
  Tangible Leverage Ratio (MRQ) 0.61
  Asset Turnover Ratio (TTM) 0.38
  Inventory Turnover Ratio (TTM) 2.17



Dynavax Technologies achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in III. Quarter 2023 to 7.47 %.

Dynavax Technologies net profit margin of 20.86 % is currently ranking no. 34 in Major Pharmaceutical Preparations industry, ranking no. 61 in Healthcare sector and number 719 in S&P 500.

More on DVAX's Key Ratios





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com